AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01603667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Study NCT01603667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Study NCT04587258 — intervention group
Intervention type: BEHAVIORAL
Intervention: Informational videos and social media campaigns encouraging cancer screening.
Description: Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
Study NCT00365417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
Study NCT01021657 — intervention group
Intervention type: PROCEDURE
Intervention: trabeculectomies, non penetrating deep sclerectomies
Study NCT02926937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study NCT02926937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study NCT02926937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study NCT00156650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
Study NCT00156650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone (T) gel 10 g daily for 6 months
Study NCT04505124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FutureMe App
Description: The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
Study NCT00156650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone
Description: 300 mg IM every 3 months
Study NCT02463019 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate
Study NCT03908307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZURDEX
Description: Implant 700 μg
Study NCT04505124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TrackingApp
Description: The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
Study NCT02028455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
Study NCT01291160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
Study NCT01291160 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Moist Wound Therapy
Description: During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
Study NCT02273427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS
Study NCT02273427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study NCT02273427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat meal
Study NCT02273427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat meal
Study NCT00493285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00493285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
Study NCT00493285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2
Study NCT03001739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil Hydrochloride Injection
Description: Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
Study NCT03001739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil Hydrochloride Injection
Description: Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
Study NCT04304248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel, Carboplatin, Toripalimab
Description: Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
Study NCT03636230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Monitoring
Description: Remote Monitoring only
Study NCT04147533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib withdrawal
Description: withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
Study NCT00062868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2
Study NCT03824236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (SB257049)
Description: Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
Study NCT04147533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
Study NCT04147533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
Study NCT01175070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of pegaptanib sodium
Description: Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
Study NCT05104931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanoformed Piroxicam IR Tablet
Description: Orally delivered Nanoformed Piroxicam
Study NCT02811341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Hydrobromide
Study NCT02811341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT05104931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoformed Piroxicam IR Tablet
Description: Orally delivered Nanoformed Piroxicam
Study NCT05104931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felden (piroxicam) Tablets
Description: orally delivered Felden (reference) tablets
Study NCT03636230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: In-Clinic visits only
Study NCT01940744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescriptive Mobilization
Description: The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits.
Study NCT01940744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic Mobilization
Description: The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
Study NCT02419911 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic surgery
Description: gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
Study NCT05104931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexidol (piroxicam) Tablets
Description: orally delivered Brexidol (reference) tablets
Study NCT01416909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Treatment
Description: Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
Study NCT03457402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shaping Delay Tolerance
Description: Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
Study NCT03457402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shaping Delay Tolerance
Description: Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
Study NCT01416909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
Study NCT03868631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein supplement
Description: 19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
Study NCT01416909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
Study NCT01416909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
Study NCT03491124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
Study NCT03491124 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Laser pointer pointed at the ear, but not turned on.
Study NCT03882515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
Study NCT03882515 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuous Surface Slip Technique
Description: 1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes.
Study NCT03882515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without intervention
Description: Evaluation and re-evaluation without intervention
Study NCT05013164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
Study NCT04478123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
Study NCT02435329 — intervention group
Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups
Study NCT03457688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: prebiotic inulin-type fructans
Study NCT03457688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo maltodextrin